anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

153,121-153,180 of 319,975

filter-aware
08
The slide uses a Gantt-style chart to represent the development status of various gene therapy programs.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Interest1 hit
09
The chart uses a staircase/waterfall visualization to show individual disease populations contributing to a total addressable market.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Interest1 hit
10
The slide uses an upward-trending arrow diagram to represent progress or acceleration.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Interest1 hit
11
The slide uses line charts to illustrate revenue or patient growth trajectories over time (Q1-Q15).Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Interest1 hit
12
The slide uses a grid layout to associate individuals with their past or current corporate affiliations via logos.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Interest1 hit
13
The slide highlights institutional credibility and R&D capabilities through a specific academic partnership.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Interest1 hit
14
The slide uses a hub-and-spoke style diagram to show how two entities contribute to a central set of activities.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Interest1 hit
15
The background features a faint image of a gel electrophoresis or DNA sequencing result, suggesting a biotech/genomics focus.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Interest1 hit
16
Includes a biological pathway diagram and a clinical progression timeline.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Logic Chain1 hit
17
The chart uses a sigmoid-like curve to show the relationship between enzyme activity and disease progression.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Logic Chain1 hit
18
The vector uses a P2A self-cleaving linker to ensure 1:1 expression of the two genes under a single promoter.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Logic Chain1 hit
19
The chart uses standard statistical significance markers (*, **, ****) to denote p-values against the control group.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Logic Chain1 hit
20
The chart displays longitudinal data for five groups: Heterozygote/Vehicle, three dose levels of TSHA-101 in Knockout mice, and Knockout/Vehicle control.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Logic Chain1 hit
21
The chart displays statistical significance markers (asterisks) comparing treatment groups to the vehicle control.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Logic Chain1 hit
22
The slide uses a table-like structure to define the parameters of a Phase 1/2 clinical trial.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Logic Chain1 hit
23
Includes a diagram of the AAV9-hCLN1 gene therapy construct.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Desire1 hit
24
The chart is a standard Kaplan-Meier survival plot used in preclinical efficacy studies.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Desire1 hit
25
The chart compares untreated WT, Het, and KO mice against treated mice at 4, 20, and 26 weeks of age.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Desire1 hit
26
The slide uses a consistent icon for each pipeline entry.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Desire1 hit
27
The background features a DNA gel electrophoresis image, suggesting a biotech or genetic focus.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Desire1 hit
28
Includes a citation for disease reversibility research.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Aha Moment1 hit
29
Includes a visual spectrum diagram showing the relationship between MECP2 expression levels and clinical outcomes.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Aha Moment1 hit
30
The slide uses a diagram to illustrate the genetic construct (scAAV ITR, MeP426, miniMECP2, miRARE).Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Aha Moment1 hit
31
The slide uses a numbered process flow (1-5) to explain a molecular biology mechanism.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · ActionLoop · Aha Moment1 hit
32
The slide shows immunohistochemistry images (NeuN, myc, DAPI, merge) for two experimental conditions across two mouse IDs each.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · ActionLoop · Aha Moment1 hit
33
The slide displays immunofluorescence staining (NeuN, myc, DAPI, merge) across three brain regions (Thalamus, Hippocampus, Brain Stem) for two treatment groups (PHP.B/mini vs PHP.B/mini-miRARE).Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · ActionLoop · Aha Moment1 hit
34
The chart shows survival rates over 35 weeks for various dosage groups of AAV9/MECP2 and TSHA-102.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · ActionLoop · Aha Moment1 hit
35
The slide compares TSHA-102 against control and other AAV9 constructs. The bottom box highlights specific adverse event rates (lesions/prolapses).Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · ActionLoop · Aha Moment1 hit
36
The chart shows survival percentages over time (weeks) for different treatment groups, with diamonds indicating vet-requested euthanasia.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · ActionLoop · Aha Moment1 hit
37
Taysha | IPO Presentation Deck | 66 slidesTaysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
38
The slide uses a consistent structure for each pipeline asset: program name, target indication, development stage, disease description, and prevalence.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
39
The background features a DNA gel electrophoresis image, reinforcing the genetic theme.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
40
The slide uses a list-based structure to detail the mechanism, clinical impact, and prevalence for each pipeline asset.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
41
The slide highlights infrastructure capabilities, specifically listing Sartorius equipment and color-coded floor plan areas.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
42
The slide includes a footnote clarifying the cash position as of June 30, 2020, adjusted for subsequent financing.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
43
The slide uses a T-shaped graphic as a visual anchor, likely referencing the company's branding or a 'T' for 'Timeline'.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
44
Taysha | IPO Presentation Deck | 66 slidesTaysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
45
The image is a classic representation of DNA sequencing or fingerprinting, often used in biotech pitch decks to signify core proprietary technology.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
46
The diagram illustrates a molecular biology workflow for AAV capsid engineering.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
47
The slide highlights the potential to bypass immune responses for gene therapy redosing.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
48
Includes a disclaimer about intellectual property rights at the bottom.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
49
The slide uses a numbered process flow (1-5) to explain a biological mechanism.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
50
The slide outlines a specific R&D process (Reg1 and MiRARE) for gene therapy target identification.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
51
The slide highlights a specific 'miRARE' target panel derived from the data analysis.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
52
The background features a gel electrophoresis image, common in biotech/genomics pitch decks.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
53
The chart is a box-and-whisker plot comparing age of onset, death, and last report across multiple genetic conditions, highlighting SURF1.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
54
Includes a molecular diagram of glycogen branching and a therapeutic component breakdown (AAV9 + hGBE1 + Intrathecal delivery).Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
55
Includes a bar chart of EPM2A/EPM2B cases by country and a biological process diagram showing the transition from glycogen to Lafora bodies.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
56
Includes a scientific diagram of glycogen branching and a bar chart showing Gys1 deficiency impact.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
57
The slide uses Kaplan-Meier survival curves and longitudinal body mass measurements to validate the therapeutic hypothesis.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
58
Includes a visual representation of MAPT mutations linked to specific FTLD-tau subtypes and a process diagram of tau aggregation.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
59
The background image is a DNA gel electrophoresis, suggesting a biotech or genetic research context.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
60
Includes a visual mechanism of action diagram showing the silencing of Ube3a-ATS to restore Ube3a expression.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
61
Includes a visual representation of the genetic mechanism (Typical vs Premutation vs Full mutation).Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
62
Includes a bar chart of clinical features and a schematic of the AAV9-shRNA mechanism.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
63
The background features a DNA gel electrophoresis image, reinforcing the genetic focus.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
64
Includes a biological diagram of the synapse and a therapeutic approach summary (AAV9 + hSLC6A1 + Intrathecal delivery).Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
65
Includes a visual equation for the therapeutic approach (AAV9 + hSLC13A5 + Intrathecal delivery).Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
66
Includes a diagram of the KCNQ2 protein structure and a visual representation of a gene therapy approach (AAV9 + hKCNQ2 + Intrathecal delivery).Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Action1 hit
01
Slide 1
Teladoc | Mergers and Acquisitions Presentation Deck | 36 slidesTeladoc | Mergers and Acquisitions Presentation Deck | 36 slides · Teladoc Health
Conference presentation Investment bank Beat · Situation & Context1 hit